| Mylan is engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (OTC) pharmaceutical products for resale by others and active pharmaceutical ingredients (API) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Co.'s API business is conducted through its subsidiary, Mylan Laboratories Limited, which is included within its Rest of World segment. Among Co.'s branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. Co.'s OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products. |
When researching a stock like Mylan NV, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from MYL Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for MYL stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the MYL 200 day moving average ("MYL 200 DMA"), while one of the most popular "shorter look-backs" is the MYL 50 day moving average ("MYL 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Mylan NV.